Upcoming translational challenges for uveal melanoma.
The past few years have witnessed major advances in the understanding of the molecular landscape of uveal melanoma (UM). The discovery of a mutational background that is completely different from the one of skin melanoma has granted to UM a stand-alone status. The absence of effective therapy for metastatic disease offers now a chessboard for targeted therapy but at the same time urges preclinical science to develop accordingly, to guide the use of economical resources to the best profit of patients. This review describes the current knowledge on the biology of this disease and discusses the challenges that must be undertaken to translate this knowledge into real benefit for patients.
Candiolo Cancer Institute - Fondazione Piemontese per la Ricerca sul Cancro (FPRC), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Candiolo, Torino 10060, Italy.
Nabil
N
Amirouchene-Angelozzi
Department of Translational Research, Institut Curie, 26 rue d'Ulm, Paris 75005, France.
Marie
M
Schoumacher
INSERM U830, Institut Curie, 26 rue d'Ulm, Paris 75005, France.
Marc-Henri
MH
Stern
Department of Ophthalmological Oncology, Institut Curie, 26 rue d'Ulm, Paris 75005, France.
Nathalie
N
Cassoux
Department of Ophthalmological Oncology, Institut Curie, 26 rue d'Ulm, Paris 75005, France.
Laurence
L
Desjardins
Department of Medical Oncology, Institut Curie, 26 rue d'Ulm, Paris 75005, France.
Sophie
S
Piperno-Neumann
INSERM U932, Institut Curie, 26 rue d'Ulm, Paris 75005, France.
Olivier
O
Lantz
Department of Translational Research, Institut Curie, 26 rue d'Ulm, Paris 75005, France.
Sergio
S
Roman-Roman
D000818:Animals; D006801:Humans; D008545:Melanoma / Q000235:genetics*; D009154:Mutation / Q000235:genetics; D012878:Skin Neoplasms; D014604:Uveal Neoplasms / Q000235:genetics*; D000096142:Cutaneous Malignant Melanoma; D000098943:Uveal Melanoma